AstraZeneca and Human Longevity (HLI) have announced a ten-year collaboration that enables HLI to sequence and analyse patient samples from AstraZeneca’s clinical trials
AstraZeneca will share up to 500,000 DNA samples, collected through the company’s clinical trials, with HLI, a genomics-based, technology-driven company.
HLI will sequence the genomes from these samples and from future samples donated over the next 10 years by patients in AstraZeneca's trials.
These data will be shared with AstraZeneca who will also gain access to HLI's database, the HLI Knowledgebase, which will have up to 1 million integrated health records with genome, molecular and clinical data by 2020, according to HLI.
AstraZeneca will work with HLI's machine learning, pattern recognition and analytical techniques to interpret the genomic data.
J Craig Venter, co-founder and CEO, HLI, said: "We are excited to establish this long term relationship with AstraZeneca who are now establishing themselves as a leader in genomic-focused research.
"We look forward to working together to use HLI's proprietary computational methods and genomic data insights to better inform clinical trials and drug development."
Financial terms of the deal were not disclosed.